98%
921
2 minutes
20
This paper was originally published under standard Springer Nature copyright. As of the date of this correction, the Analysis is available online as an open-access paper with a CC-BY license. No other part of the paper has been changed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608346 | PMC |
http://dx.doi.org/10.1038/s41592-018-0193-x | DOI Listing |
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Front Immunol
August 2025
Department of Gynaecology, Laoning Cancer Hospital and Institute, Shenyang, China.
[This corrects the article DOI: 10.3389/fimmu.2025.
View Article and Find Full Text PDFFront Immunol
August 2025
Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
[This corrects the article DOI: 10.3389/fimmu.2023.
View Article and Find Full Text PDFFront Immunol
August 2025
Immunobiology Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
[This corrects the article DOI: 10.3389/fimmu.2025.
View Article and Find Full Text PDF[This corrects the article DOI: 10.17816/CP15491.].
View Article and Find Full Text PDF